Omeros (OMER)
(Delayed Data from NSDQ)
$3.30 USD
-0.02 (-0.45%)
Updated May 29, 2024 04:00 PM ET
After-Market: $3.31 +0.01 (0.30%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
Brokerage Reports
Omeros Corporation [OMER]
Reports for Purchase
Showing records 161 - 180 ( 423 total )
Company: Omeros Corporation
Industry: Medical - Products
Initial Results for OMS721 Treatment of Complement Related Kidney Diseases Look Promising, in Our View; Reiterate OUTPERFORM and $56 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
October and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
September and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
HEALTHCARE - 2016 PacGrow Healthcare Conference Day 2
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Omeros Corporation
Industry: Medical - Products
Financing Covers the Development of OMS721 and Pipeline; Reiterate OUTPERFORM but Reducing Price Target to $56 due to Share Count Increase
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Q2 Financials: Beat and Beat--More OMS721 Phase 2 Results - Start of Phase 3 in H2; Reiterate OUTPERFORM and $62 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
August and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences: Upcoming Events for the Week of July 18
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Omeros Corporation
Industry: Medical - Products
July and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences: Upcoming Events for the Week of July 4
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences: Upcoming Events for the Week of June 27
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of June 6
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Omeros Corporation
Industry: Medical - Products
June and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Q1 Update: OMIDRIA Sales Accelerating into Q2 and 2016 Catalysts Suggest Buying on Weakness to Us; Reiterate OUTPERFORM and $62 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
May and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Dropping Coverage
Provider: Roth Capital Partners, Inc.
Company: Omeros Corporation
Industry: Medical - Products
April and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Q4/FY:15 Update; Omidria Sales Beat Consensus; Phase 3 Trial for OMS721 Set to Begin Later this Year; Reiterate OUTPERFORM and $62 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L